linjc16/ctgov huggingface dataset:
Prevalence of Anatomical Variants of Dural Sinuses by MRV Evaluation in Sohag

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to use the MRV to depict the prevalence of anatomical variants of dural venous sinuses in Sohag population, which can help to avoid potenital pitfalls in the diagnosis of dural venous sinus thrombosis, venous infarcts and venous hemorrhage.

Official Title
-----------------
Prevalence of Anatomical Variants of Dural Sinuses by MRV Evaluation in Sohag

Conditions
-----------------
Anatomical Variants of Dural Sinuses by MRV

Intervention / Treatment
-----------------
* Device: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sohag by nationality and residence, male or female by sex, having normal cerebral MRV reported and consented to participate in the research work will be included in this research. Exclusion Criteria: Having the diagnosis of cerebral venous sinus thrombosis, congential or acquired intracranial abnormalities, ischemic or hemorrhagic stroke, intracranial hypertension, intracranial space occuping lesion, and previous head injury or neurosurgery, also patients with absolute or relative contraindications for imaging including claustrophobia, metallic implants, pacemaker and prosthetic heart valves for MRI.
Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: MRI|To detect prevalence of anatomical variants of dural sinuses by MRV|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of anatomical variants of dural sinuses in Sohag population | Number of anatomical variants of dural sinuses by MRV evaluation in Sohag | 8 months |
Volatile Non-Invasive Biomarkers of Epileptic Seizures

Study Overview
=================
Brief Summary
-----------------
Breath and sweat samples will be collected from people who have been admitted to hospital after a potential seizure and analysed by the team. The researchers then hope to identify a pattern of small molecules that can distinguish seizures from other events, and perhaps determine the severity of the seizure.

Detailed Description
-----------------
Determining whether someone has had an epileptic seizure, or another event, can be challenging and result in the wrong diagnosis. A 'seizure test' used after the event would therefore be very helpful. Researchers have used small molecules released from the body in breath and sweat to detect cancers and other diseases; this study will determine whether a similar method can be used to detect whether someone has had an epileptic seizure.

Official Title
-----------------
Volatile Non-Invasive Biomarkers of Epileptic Seizures

Conditions
-----------------
Epilepsy, Non-Epileptic Seizure

Intervention / Treatment
-----------------
* Other: Sample Collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have been admitted to either University College London's Queen's Square EEG-telemetry unit or Chalfont Centre for Epilepsy, for diagnosis of seizure events. Patients aged 18 years or above Exclusion Criteria: Patients with active infection or who have taken antibiotics within 4 weeks Patients on immunosuppressive medications Patients with co-morbidities preventing breath collection Patients unable to provide informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Sample Collection|Patients will have breath samples collected by blowing into a bag, and sweat samples collected by gauze. These samples will be collected at various timepoints whilst the patients are admitted on the ward.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distinguishing epileptic from non-epileptic seizures | To distinguish epileptic from non-epileptic seizures with the detection of volatile organic compounds (VOCs) in breath and sebum samples. | 3 years |
TAP Block vs Spinal Orphine for Postoperative Caesarean Section Analgetics

Study Overview
=================
Brief Summary
-----------------
The goal of this randomized controlled trial is to compare the effect of TAP block vs spinal morphine for post caesarean section analgesics. The main questions it aims to answer are: Which post op analgesic method works better for patients who underwent caesarean section The number of additional opioid needed

Official Title
-----------------
Comparison of Post-operative Analgetics With Transversus Abdominis Block and Spinal Morphine for Post-Caesarean Section: A Randomised Trial Study

Conditions
-----------------
Post Operative Pain

Intervention / Treatment
-----------------
* Procedure: Transversus Abdominal Plane Block
* Procedure: Spinal Morphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Indicated for caesarean section as assessed by Obstetricians ASA II Consented to be included in the study Exclusion Criteria: Allergy history Spinal converted to general anesthesia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Transversus Abdominis Plane Block<br>Twenty two subjects were given postoperative block administration in the transversus abdominis area on each side with ultrasonography (USG) guidance | Procedure: Transversus Abdominal Plane Block<br>* 20 cc of bupivacaine 0.2% was given to the transversus abdominis plane<br>|
| Active Comparator: Spinal Morphine<br>Twenty two subjects were given additional morphine 100 µg intrathecally | Procedure: Spinal Morphine<br>* 100 µg was administered intrathecally preoperatively<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of time the patient needed the first additional opioid analgesics |  | 24 hours post operative | 
| Total need for additional opioids |  | 24 hours post operative |
Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Study Overview
=================
Brief Summary
-----------------
Provide expanded access of cemiplimab in patients with solid tumors

Detailed Description
-----------------
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.

Intervention / Treatment
-----------------
* Drug: Cemiplimab


Participation Criteria
=================
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Cemiplimab|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Depot-medroxy Progesterone Acetate Injectable Contraceptives in Lactating Women 1st Week Versus 6 Week Postpartum Initiation

Study Overview
=================
Brief Summary
-----------------
This study aims to identify the effect of using Depot-medroxy progesterone acetate injectable contraceptives on lactating women mother and infant in 1st week versus 6th week postpartum initiation. This study is open labeled -randomized clinical trial was used. It was conducted at woman's health hospital, Assuit University. This study applied on 120 lactating women, who divided into two equal group I (who used DMPA injectable in the 1st week postpartum) and group II (who used DMPA injectable in the 6th week postpartum). Each group included 60 lactating women). Follow up was carried out after 3 months from the first dose to determine the changes in the studied women's menstrual period, weight, breast feedings…etc.

Official Title
-----------------
Depot-medroxy Progesterone Acetate Injectable Contraceptives in Lactating Women 1st Week Versus 6 Week Postpartum Initiation

Conditions
-----------------
Complications of DMPA Injectable Contraceptives

Intervention / Treatment
-----------------
* Device: Depot-medroxy Progesterone Acetate Injectable Contraceptives


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Desire contraception for at least one year Apparently healthy participant Age 20- 40 years old Term delivery Birth weight >2.5 kg multipara Intend to breastfeed at time of hospital discharge Those delivered normally or by caesarean section Ready to follow and need immediate contraception Exclusion Criteria: Maternal health problems (DM, HTN, cardiac disease, anaemia, or any other obvious problem) Any maternal complications during labour Preterm delivery IUGR

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Women using DMPA after 6 weeks postpartum<br> | Device: Depot-medroxy Progesterone Acetate Injectable Contraceptives<br>* Depot-medroxy progesterone acetate injectable contraceptives<br>|
| Experimental: Women using DMPA after 1 week postpartum<br> | Device: Depot-medroxy Progesterone Acetate Injectable Contraceptives<br>* Depot-medroxy progesterone acetate injectable contraceptives<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pattern of vaginal bleeding postpartum | Number of bleeding days- number of pads per day | 2021 to 2023 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration and frequency of breast milk | score of frequency of breast feeding | 2021 to 2023 |
Conduction System Pacing With INGEVITY+

Study Overview
=================
Brief Summary
-----------------
The study is intended to evaluate the safety and effectiveness of the Boston Scientific INGEVITY+ cardiac pacing lead when implanted in the left bundle branch area (LBBA).

Detailed Description
-----------------
INSIGHT is a prospectively defined analysis of INGEVITY+ leads that have been previously implanted in the LBBA for the purpose of anti-bradycardia pacing. The results will provide complication free rate (safety) and lead measurements (performance). Data will be gathered by means of a retrospective, multi-center, US only observational chart review to obtain data on INGEVITY+ leads implanted in the LBBA. Additional data will be gathered from the pulse generator and from the LATITUDE remote monitoring system for pacing thresholds and R-wave amplitude. Consecutive implants will be collected from each site for evaluating the endpoints.

Official Title
-----------------
ConductIoN System pacInG witH IngeviTy+ for the Left Bundle Branch Area

Conditions
-----------------
Bradycardia

Intervention / Treatment
-----------------
* Device: Cardiac pacing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for Primary Analysis: De novo anti-bradycardia pacing pacemaker implant. INGEVITY+ lead implant attempt in the LBBA as documented in the medical record at least 90 days ago. LBBAP implant attempt employed a Boston Scientific SSPC series sheath Exclusion Criteria for Primary Analysis: -ICD and CRT-D devices

Ages Eligible for Study
-----------------
Minimum Age: 1 Day

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| LBBA INGEVITY+ Pacing<br>Patients indicated for anti-bradycardia pacing that have been implanted with an INGEVITY+ lead in the LBBA. | Device: Cardiac pacing<br>* Patient's previously implanted with the INGEVITY+ lead located in the LBBA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lead-Related Complication Free Rate | Adverse events that require correction with an invasive intervention or resulted in significant loss of device functionality. | Implant through 90 days | 
| Pacing Threshold | Percent of INGEVITY+ leads with pacing capture threshold measurement of less than or equal to 2V. | Implant through 90 days | 
| Sensed R-wave amplitude | Percent of INGEVITY+ leads with an R-wave amplitude greater than 5mV. | Implant through 90 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Conduction system pacing, Cardiac physiologic pacing
Follow-up Strategy for Esophageal Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The recurrence risk of patients with esophageal cancer was stratified by integrating different stages and pathological factors. The risk of recurrence was dynamically estimated for each group of patients, and the optimal follow-up strategy was developed based on the recurrence risk.

Detailed Description
-----------------
Patients with histologically proven, esophageal cancer (EC) patients diagnosed between 2008 and 2018 were recruited. Recursive partition analysis was applied to develop recurrence risk stratification for patients. The follow-up strategies of each stratification were developed based on monthly recurrence probability and validated by bootstrap validation and an external dataset. Markov decision-analytic models were constructed to evaluate the cost-effectiveness of the follow-up strategies.

Official Title
-----------------
An Optimized Post-surgery Follow-up Strategy for Patients With Esophageal Cancer

Conditions
-----------------
Esophagus Cancer

Intervention / Treatment
-----------------
* Other: follow-up with different time intervals


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (1) Patients aged between 18 and 80 years old; (2) Pathological diagnosis as esophageal squamous cell carcinoma or adenocarcinoma; (3) Patients underwent esophagectomy and received R0 resection. Exclusion Criteria: (1) Patients with secondary primary tumor; (2) Patients who died within 30 days after surgery or died of post-operation complications; (3) Patients missing essential clinical information, such as operation record, pathological diagnosis, and follow-up data; (4) Patients with radiologically or histologically confirmed distant metastasis; (5) Patients previously underwent endoscopic mucosal resection or definitive radiochemotherapy as initial treatment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| follow-up<br>patients were follow-up with different time intervals | Other: follow-up with different time intervals<br>* After radical surgery, patients are followed up with different time intervals<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| disease-free survival | disease-free survival | 2008-2020 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| local relapse-free survival |  | 2008-2020 | 
| distant metastasis-free survival |  | 2008-2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
follow-up
Machine Learning Models for Prediction of Acute Kidney Injury After Noncardiac Surgery

Study Overview
=================
Brief Summary
-----------------
Acute kidney injury (AKI) is a common surgical complication characterized by a rapid decline in renal function. Patients with AKI are at an increased risk of developing chronic kidney disease and end-stage renal disease, which has been associated with an increased risk of morbidity, mortality and financial burdens. Identifying high-risk patients for postoperative AKI early can facilitate the development of preventive and therapeutic management strategies, and prediction models can be helpful in this regard. The goal of this retrospective study is to develop prediction models for postoperative AKI in noncardiac surgery using machine learning algorithms, and to simplify the models by including only preoperative variables or only important predictors.

Official Title
-----------------
Development of Interpretable Machine Learning Models for Prediction of Acute Kidney Injury After Noncardiac Surgery

Conditions
-----------------
Postoperative Acute Kidney Injury

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (age ≥ 18 years) who had a serum creatinine measurement within 10 days before surgery and at least one measurement within 7 days after surgery. Eligible surgeries encompassed general, thoracic, orthopedic, obstetric, gynecology, and neurosurgery procedures lasting longer than 1 hour Exclusion Criteria: Patients with concurrent cardiac, vascular, urological, or transplant surgeries. Patients with an American Society of Anesthesiologists (ASA) physical status V. Patients with end-stage renal disease (i.e., a glomerular filtration rate [eGFR] of 15 mL/min/1.73 m² or receiving hemodialysis).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative acute kidney injury | In accordance with the KDIGO creatinine criteria: a serum creatinine increases of 26.5 mmol/L within 48 hours or 1.5 times baseline within 7 days after surgery. | Within 7 days after surgery |
Integrated Neuromuscular Inhibition Technique and Myofascial Release on Cervical Range of Motion and Dysfunction

Study Overview
=================
Brief Summary
-----------------
to findout the improvement by Integrated Neuromuscular Inhibition Technique and Myofascial Release on Cervical Range of Motion and Dysfunction

Official Title
-----------------
Comparison of The Effects of The Integrated Neuromuscular Inhibition Technique and Myofascial Release on Cervical Range of Motion and Dysfunction in Individuals With Nonspecific Cervical Pain

Conditions
-----------------
Myofascial Trigger Point Pain

Intervention / Treatment
-----------------
* Diagnostic Test: Integrated Neuromuscular Inhibition Technique
* Diagnostic Test: Myofascial Release


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ● Age between 25-40 Both males and females included Participants suffering from recent cervical pain without any pathology. Exclusion Criteria: ● Participants having cervical radiculopathy Having recent trauma of the cervical spine Non-cooperative subject

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Neuromuscular Inhibition Technique<br> | Diagnostic Test: Integrated Neuromuscular Inhibition Technique<br>* Exercises<br>|
| Other: Myofascial Release<br> | Diagnostic Test: Myofascial Release<br>* Exercises<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cervical Range of Motion measurement |  | 6 Months |
Consequences of COVID-19 Infection for Child Health and Wellbeing: Protocol for a Prospective, Observational, Longitudinal Study in Children

Study Overview
=================
Brief Summary
-----------------
Prospective follow-up of children with SARS-CoV-2

Official Title
-----------------
Consequences of COVID-19 Infection for Child Health and Wellbeing: Protocol for a Prospective, Observational, Longitudinal Study in Children

Conditions
-----------------
Long COVID

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children aged 0-18 years The child sought/needed primary or secondary medical care for COVID-19 Laboratory (RT-PCR,) [18] 28 days - 3 months from the onset of COVID-19 symptoms Parent's/carer's/guardian's consent to participate Exclusion Criteria: adults

Ages Eligible for Study
-----------------
Minimum Age: 4 Weeks
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of children developing long covid | prevalence of post covid condition at 3-6-12-18-24-36 months after SARS-CoV-3 infection | up to 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| duration and characteristics of children with long covid, also according to variants | prevalence of post covid condition according to the original SARS-CoV-2 variant at 3-6-12-18-24-36 months after SARS-CoV-3 infection | up to 36 months |